13F Holdings
中文EN

KRRO Korro Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1703647 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-82.5%
TTM net income YoY-20.0%
TTM EPS YoY5.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,467.3%
Net margin-8,214.5%
FCF margin-4,943.8%
EBITDA margin-8,325.8%

Returns

ROE-113.3%
ROA-68.5%
ROIC (approx.)-140.5%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets40.3%
Debt / equity0.00x
Current ratio7.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.60x
Accruals ratio-27.4%
Payout ratio—
Capex / revenue13.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6.39M$2.27M$0$0$14.07M
R&D expense$65.58M$63.64M$57.25M$42.20M$60.92M
SG&A expense$28.16M$30.55M$27.28M$16.80M$37.18M
Operating income-$121.86M-$91.91M-$84.53M-$59.00M-$84.03M
Interest expense———$961,000$764,000
Pretax income-$116.62M-$83.44M-$81.14M-$58.02M-$84.67M
Income tax$637,000$141,000$27,000$10,000$15,000
Net income-$117.26M-$83.58M-$81.17M-$58.03M-$84.69M
EBITDA-$117.58M-$88.34M-$80.90M-$56.49M-$81.26M
EPS (basic)-12.48-9.37-53.08-227.42-2.47
EPS (diluted)-12.48-9.37-53.08-227.42-2.47
Weighted avg. shares (diluted)9.40M8.92M1.53M255,17534.35M
Banking
Net interest income——$0-$118,000—
Balance sheet
Cash & equivalents$21.82M$55.64M$166.15M$36.33M$79.64M
Short-term investments$53.33M$70.45M$0$18.91M$51.07M
Current assets$82.37M$131.53M$172.73M$57.08M$134.75M
PP&E, net$8.16M$27.71M$15.66M$9.87M$5.52M
Total assets$113.51M$226.24M$221.66M$73.74M$185.36M
Current liabilities$11.94M$14.96M$19.48M$8.70M$11.43M
Short-term debt———$10.00M$833,000
Total liabilities$62.07M$65.83M$51.75M$8.91M$54.53M
Shareholders' equity$51.44M$160.41M$169.91M-$99.03M-$42.21M
Shares outstanding9.42M9.38M8.02M268,46834.61M
Cash flow statement
Operating cash flow-$78.56M-$60.07M-$67.28M-$53.65M-$76.06M
Capital expenditure$518,000$17.90M$7.84M$5.14M$2.91M
Free cash flow-$79.08M-$77.98M-$75.12M-$58.78M-$78.97M
Investing cash flow$43.99M-$123.35M$11.16M$11.06M-$66.13M
Financing cash flow$685,000$69.36M$187.76M$18,000$1.36M
Depreciation & amortization$4.28M$3.56M$3.63M$2.51M$2.77M
Stock-based compensation$7.66M$4.46M$2.38M$1.14M$21.75M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.